Hansa Biopharma; FDA opens the door for the next pivotal Phase 3 study

Just a moment...

(www.redeye.se)

Uddrag: "In our view, Hansa Biopharma’s ability to progress the progress of the anti-GBM opportunity for the imlifidase platform is distinctly positive. This follows a successful pre-IND meeting with the FDA. Recently we have seen several FDA delays in this sector, and Hansa’s ability to timely progress this candidate to the third pivotal Phase 3 trial is an achievement."

"....... Our base case value proposition is SEK 410 (Bear SEK 175 and Bull SEK 600)."